The superbugs: Evolution, dissemination and fitness

Current Opinion in Microbiology

Volumn 1, Issue 5, 1998, Pages 524-529

  Morris, Andrew ^a   Kellner, James D ^b   Low, Donald E ^a  

^a MOUNT SINAI HOSPITAL   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; BACTERIUM; CROSS INFECTION; DRUG EFFECT; EVOLUTION; HUMAN; MICROBIOLOGY; PHYSIOLOGY; REVIEW;

ANTI-BACTERIAL AGENTS; BACTERIA; CROSS INFECTION; DRUG RESISTANCE, MICROBIAL; EVOLUTION; HUMANS;

EID: 0032173614     PISSN: 13695274     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1369-5274(98)80084-2     Document Type: Article

References (70)

1. Holland HD: Geochemistry-evidence for life on Earth more than 3850-million years ago. Science 1998, 275:38-39.
2. O'Brien TF: The global epidemic nature of antimicrobial resistance and the need to monitor and manage it locally. Clin Infect Dis 1997, 24(suppl 1): S2-S8.
3. Gold HS, Moellering RCJ: Antimicrobial-drug resistance. N Engl J Med 1 996, 335:1445-1453.
4. Levin BR, Antia R, Berliner E, Bloland P, Bonhoeffer S, Cohen M, Derouin T, Fields PI, Jafari H, Jernigan D et al: Resistance to antimicrobial chemotherapy: a prescription for research and action. Am J Med Sci 1998, 315:87-94. A comprehensive overview of the nature and the source of the problem of antimicrobial resistance and suggestions as to what procedures could be employed to stem this increase in resistance.
5. Bonafede M, Rice LB: Emerging antibiotic resistance. J Lab Clin Med 1997, 130:558-566. An excellent understandable review of three important resistant mechanism and their clinical impact: extended spectrum β-lactamases, penicillin-resistant S. pneumoniae, and vancomycin-resistant enterococci.
6. Rasheed JK, Jay C, Metchock B, Berkowitz F, Weigel L, Crellin J, Steward C, Hill B, Medeiros AA, Tenover FC: Evolution of extended-spectrum beta-lactam resistance (SHV-S) in a strain of Escherichia coli during multiple episodes of bacteremia. Antimicrob Agents Chemother 1997, 41:647-653.
7. Deplano A, Zekhnini A, Allali N, Couturier M, Struelens MJ: Association of mutations in gyrA and gyrA topoisomerase genes with resistance to ciprofloxacin in epidemic and sporadic isolates of methicillin-resistant Staphytococcus aureus. Antimicrob Agents Chemother 1997, 41:2023-2025.
8. Riesenfeld C, Everett M, Piddock LJ, Hall BG: Adaptive mutations produce resistance to ciprofloxacin. Antimicrob Agents Chemother 1997, 41:2059-2060.
9. Taddei F, Matic I, Godelle B, Radman M: To be a mutator, or how pathogenic and commensal bacteria can evolve rapidly. Trends Microbiol 1997, 5:427-428. A brief overview of how bacteria cope with changes that on the one hand give them an advantage in colonizing their hosts, such as increased virulence, while on the other hand impairing their ability to compete with other microorganisms.
10. LeClerc JE, Li B, Payne WL, Cebula TA: High mutation frequencies among Escherichia coli and Salmonella pathogens [see comments]. Science 1996, 274:1208-1211.
11. Bjorkman J, Hughes D, Andersson DI: Virulence of antibiotic-resistant Salmonella typhimurium. Proc Natl Acad Sci USA 1998, 95:3949-3953.
12. Courvalin P: The Garrod Lecture. Evasion of antibiotic action by bacteria. J Antimicrob Chemother 1996, 37:855-869.
13. Coffey TJ, Enright MC, Daniels M, Wilkinson P, Berron S, Fenoll A, Spratt BG: Serotype 19A variants of the Spanish serotype 23F multiresistant clone of Streptococcus pneumoniae. Microb Drug Resist 1998, 4:51-55.
14. Salyers AA, Shoemaker NB, Li LY: In the driver's seat: the Bacteroides conjugative transposons and the elements they mobilize. J Bacteriol 1995, 177:5727-5731.
15. Sandvang D, Aarestrup FM, Jensen LB: Characterisation of integrons and antibiotic resistance genes in Danish multiresistant Salmonella enterica Typhimurium DT104. FEMS Microbiol Lett 1998, 160:37-41.
16. Recchia GD, Hall RM: Origins of the mobile gene cassettes found in integrons. Trends Microbiol 1997, 5:389-394. An excellent review of the mechanisms and importance of integrons with respect to the dissemination of antimicrobial resistance.
17. Collis CM, Hall RM: Expression of antibiotic resistance genes in the integrated cassettes of integrons. Antimicrob Agents Chemother 1995, 39:155-162.
18. Hansson K, Skold O, Sundstrom L: Non-palindromic attl sites of integrons are capable of site-specific recombination with one another and with secondary targets. Mol Microbiol 1997, 26:441-453.
19. Office of Technology: Office of Technology Assessment Impacts of Antibiotic-Resistant Bacteria. Washington, DC: Office of Technology, US Congress; 1995.
20. Seppala H, Klaukka T, Vuopio-Varkila J, Muotiala A, Helenius H, Lager K, Huovinen P: The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. The Finnish Study Group For Antimicrobial Resistance. N Engl J Med 1997, 337:441-446. An example of how a country successfully tackled the problem of the emergence of antimicrobial resistance.
21. Salyers AA, Amabile-Cuevas CF: Why are antibiotic resistance genes so resistant to elimination? Antimicrob Agents Chemother 1997, 41:2321-2325. A review of the numerous ways that in which bacteria have been able to disseminate resistance elements with little or no cost to their fitness and how this may thwart our attempts to control or eliminate such resistance strains.
22. Spratt BG: Antibiotic resistance: counting the cost. Curr Biol 1996, 6:1219-1221.
23. Schrag SJ, Perrot V, Levin BR: Adaptation to the fitness costs of antibiotic resistance in Escherichia coli. Proc R Soc Lond B Biol Sci 1997, 264:1287-1291.
24. Bush K: Is it important to identify extended-spectrum beta-lactamase-producing isolates? [editorial]. Eur J Clin Microbiol Infect Dis 1996, 15:361-364.
25. Evers S, Quintiliani RJ, Courvalin P: Genetics of glycopeptide resistance in enterococci. Microb Drug Resist 1996, 2:219-223.
26. Satcher D: Emerging infections: getting ahead of the curve. Emerg Infect Dis 1995, 1:1-6.
27. Kellner JD, Mcgeer A, Cetron MS, Low DE, Butler JC, Matlow A, Talbot J, Ford-Jones EL: The use of Streptococcus pneumoniae nasopharyngeal isolates from healthy children to predict features of invasive disease. Pediatr Infect Dis J 1998, 17:279-286. This study demonstrates how a non-invasive technique can predict what stains of S. pneumoniae are likely cause invasive disease.
28. Kristinsson KG: Epidemiology of penicillin resistant pneumococci in Iceland. Microb Drug Resist 1995,1:121-125.
29. Roman RS, Smith J, Walker M, Byrne S, Ramotar K, Dyck B, Kabani A, Nicolle LE: Rapid geographic spread of a methicillin-resistant Staphylococcus aureus strain. Clin Infect Dis 1997, 25:698-705.
30. Low DE, Scheld WM: Strategies for stemming the tide of . antimicrobial resistance. JAMA 1998, 279:394-395. An overview of the issues that we must deal with if we are going to tackle the problem of increasing antimicrobial resistance.
31. Guillemot D, Carbon C, Balkau B, Geslin P, Lecoeur H, Vauzelle-Kervoroëdan F, Bouvenot G, Eschwege E: Low dosage and long treatment duration of B-lactam: risk factors for the carriage of penicillin-resistant Streptococcus pneumoniae. JAMA 1998, 279:365-370. One of the only studies that has looked at how the types and dosage of antimicrobials may be one of the driving forces that facilitate the dissemination of antimicrobial resistance.
32. Pablos-Mendez A, Raviglione MC, Laszlo A, Binkin N, Rieder HL, Bustreo F, Cohn DL, Lambregts-Van Weezenbeek CS, Kim SJ, Chaulet P, Nunn P: Global surveillance for antituberculosis-drug resistance, 1994-1997. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance [see comments], N Engl J Med 1998, 338:1641-1649. Data is presented which suggest that there is a serious threat to global tuberculosis control efforts, and that the findings should be a call to action.
33. Snider DEJ, Castro KG: The global threat of drug-resistant tuberculosis [editorial; comment]. N Engl J Med 1998, 338:1689-1690. The global threat of drug-resistant tuberculosis is as much a societal problem as it is an evolutionary problem.
34. Roberts RB, De Lencastre A, Eisner W, Severina EP, Shopsin B, Kreiswirth BN, Tomasz A: Molecurlar epidemiology of methicillin-resistant Staphylococcus aureus in 12 New York hospitals. MRSA Collaborative Study Group. J Infect DIR 1998, 178:164-171.
35. Archer GL: Staphylococcus aureus: a well-armed pathogen. Clin Infect Dis 1998, 26:1179-1181.
36. Chambers HF: Methicillin resistance in staphylococci: molecular and biochemical basis and clinical implications. Clin Microbiol Rev 1997, 10:781-791. An excellent review of the mechanisms of methicillin resistance in staphylocouci and what alternative treatment regimens are available.
37. Maranan MC, Moreira B, Boyle-Vavra S, Daum RS: Antimicrobial resistance in staphylococci. Epidemiology, molecular mechanisms, and clinical relevance. Infect Dis Clin North Am 1997, 11:813-849.
38. Turnidge JD, Nimmo GR, Francis G: Evolution of resistance in Staphylococcus aureus in Australian teaching hospitals. Australian Group on Antimicrobial Resistance (AGAR). Med J Aust 1996, 164:68-71.
39. Speller DC, Johnson AP, James D, Marples RR, Charlett A. George RC: Resistance to methicillin and other antibiotics in isolates of Staphylococcus aureus from blood and cerebrospinal fluid, England and Wales, 1989-95 [see comments]. Lancet 1997, 350:323-325.
40. Harbarth S, Rutschmann O, Sudre P, Pittet D: Impact of methicillin resistance on the outcome of patients with bacteremia caused by Staphylococcus aureus. Arch intern Med 1998, 158:182-189.
41. Steinberg JP, Clark CC, Hackman BO: Nosocomial and community-acquired Staphylococcus aureus bacteremias from 1980 to 1993: impact of intravascular devices and methicillin resistance [see comments]. Clin Infect Dis 1996, 23:255-259.
42. Herold BC, Immergluck LC, Maranan MC, Lauderdale DS, Gaskin RE, Boyle-Vavra S, Leitch CD, Daum RS: Community-acquired methicillin-resistant Staphylococcus aureus in children with no identified predisposing risk [see comments]. JAMA 1998, 279:593-598.
43. Boyce JW: Are the epidemiology and microbiology of methicillin-resistant Staphylococcus aureus changing? [editorial; comment]. JAMA 1998, 279:623-624.
44. Embil J, Ramotar K, Romance L, Alfa M, Conly J, Cronk S, Taylor G, Sutherland B, Louie T, Henderson E: Methicillin-resistant Staphylococcus aureus in tertiary care institutions on the Canadian prairies 1990-1992. Infect Control Hosp Epidemiol 1994, 15:646-651.
45. Maguire GP, Arthur AD, Boustead PJ, Dwyer B, Currie BJ: Emerging epidemic of community-acquired methicillin-resistant Staphylococcus aureus infection in the Northern Territory. Med J Aust 1996, 164:721-723.
46. Glynn MK, Bopp C, Dewitt W, Dabney P, Mokhtar M, Angulo FJ: Emergence of multidrug-resistant Salmonella enterica serotype typhimurium DT104 infections in the United States. N Engl J Med 1998, 338:1333-1338. Another example of where the misuse of antibiotics in agriculture has resulted in the emergence of a fit multidrug resistant organism that can cause invasive disease in humans become a major cause of disease in humans after contact with contaminated food.
47. Van Den Bogaard AE, Jensen LB, Stobberingh EE: Vancomycin resistant enterococci in turkeys and farmers [letter]. N Engl J Med 1997, 337:1558-1559. More evidence that vancomycin-resistant enterococci originated in agriculture, where glycopeptides have been used for years as growth promoters, and disseminated to humans.
48. Gniadkowski M, Schneider I, Jungwirth R, Hrymewicz W, Bauernfeind A: Ceftazidime-resistant Enterobacteriaceae isolates from three Polish hospitals: identification of three novel TEM- and SHV-5-type extended-spectrum beta-lactamases. Antimicrob Agents Chemother 1998, 42:514-520.
49. Poyart C, Mugnier P, Quesne G, Berche P, Trieu-Cuot P: A novel extended-spectrum TEM-type beta-lactamase (TEM-52) associated with decreased susceptibility to moxalactam in Klebsiella pneumonias. Antimicrob Agents Chemother 1996, 42:108-113.
50. Bret L, Chanal-Claris C, Sirot D, Chaibi EB, Labia R, Sirot J: Chromosomally encoded AmpC-Type β-lactamase in a clinical isolate of Proteus mirabilis. Antimicrob Agents Chemother 1998, 42:1110-1114.
51. Jacoby GA: Extended-spectrum beta-lactamases and other enzymes providing resistance to oxyimino-beta-tactams. Infect Dis Clin North Am 1997, 11:875-887. An overview of this mechanism of resistance and its effect on patient care.
52. Rasmussen BA, Bush K: Carbapenem-hydrolyzing beta-lactamases [see comments]. Antimicrob Agents Chemother 1997, 41:223-232.
53. Moellering RCJ: Vancomycin-resistant enterococci. Clin Infect Dis 1998, 26:1196-1199.
54. Vila J: Mechanisms of antimicrobial resistance in Acinetobacter baumannii. Rev Med Microbiol 1998, 9:87-97.
55. Denton M, Kerr KG: Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophilia. Clin Microbiol Rev 1998, 11:57-80.
56. Quagliarello VJ. Scheid WM: Treatment of bacterial meningitis. N Engl J Med 1997, 336:708-716. An excellent review of the treatment of bacterial meningitis and how the emergence of resistance has necessitated a change in our approach to its management.
57. American Academy Of Pediatrics Committee On Infectious Diseases: Therapy for children with invasive pneumococcal infections. Pediatrics 1997, 99:289-299. A comprehensive review of the therapy of invasive pneumococcal disease, especially in light of the recent emergence of penicillin resistance.
58. Craig WA: The future - can we learn from the past? Diagn Microbiol Infect Dis 1997, 27:49-53. A review of how we can use pharmacokinetics and pharmacodynamics to help use more rationally use antimicrobials, in these times of decreasing susceptibilities our first line antibiotics to bacteria causing common infections.
59. Klugman KP: Epidemiology, control and treatment of multiresistant pneumococci. Drugs 1996, 52(suppl 2):42-46.
60. Campbell GD Jr, Silberman R: Drug-resistant Streptococcus pneumoniae. Clin Infect Dis 1998, 26:1188-1195.
61. Low DE: Resistance issues and treatment implications: Pneumococcus, Staphylococcus aureus, and Gram-negative rods. In Infectious Disease Clinics of North America on Lower Respiratory Tract Infections. Edited by Mandell GL, Neiderman MS. Philadelphia, PA: WB Saunders Company; 1998: in press. An attempt to put in perspective as to how the emergence of resistance in common respiratory pathogens impacts the use of first line antimicrobials for community acquired pneumonia.
62. Goldstein FW: Choice of an oral beta-lactam antibiotic for infections due to penicillin-resistant Streptococcus pneumoniae. Scand J Infect Dis 1997, 29:255-257. Pharmacokinetic and pharmacodynamic data which helps decide on the most appropriate antimicrobial therapy for resistant pneumococci.
63. Doern GV, Ferraro MJ, Brueggemann AB, Ruoff KL: Emergence of high rates of antimicrobial resistance among viridans group streptococci in the United States. Antimicrob Agents Chemother 1996, 40:891-894.
64. Konig A, Reinert RR, Hakenbeck R: Streptococcus mitis with unusually high level resistance to β-lactam antibiotics. Microb Drug Resist 1998, 4:45-49.
65. Hiramatsu K, Aritaka N, Hanaki H, Kawasaki S, Hosoda Y, Hon S, Fukuchi Y, Kobayashi I: Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 1997, 350:1670-1673. The first report on the appearance of methicillin-reaistant S. aureus with reduced susceptibility to vancomycin, the mainstay for the treatment of these organisms.
66. Tenover FC, Lancaster MV, Hill BC, Steward CD, Stocker SA, Hancock GA, O'Hara CM, Clark NC, Hiramatsu K: Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides. J Clin Microbiol 1998, 36:1020-1027. A guide to help the routine laboratory to identify strains of staphylococci with reduced susceptibility to vancomycin.
67. Hanaki H, Labischinski H, Sasaki K, Kuwahara-Arai K, Inaba Y, Hiramatsu K: Mechanism of vancomycin resistance in MRSA strain Mu50. Jpn J Antibiot 1998, 51:237-247.
68. Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover FC: Methicillin-resistant Staphylococcus aureus clinical strian with reduced vancomycin susceptibiltiy. J Antimicrob Chemother 1997, 40:135-136.
69. Centers For Disease Control: Staphylococcus aureus with reduced susceptibility to vancomycin - United States, 1997. Morbid Mortal Weekly Rep 1997, 46:765-766.
70. Levin BR, Lipsitch M, Perrot V, Schrag S, Antia R. Simonsen L, Walker NM, Stewart FM: The population genetics of antibiotic resistance. Clin Infect Dis 1997, 24(suppl 1):S9-S16.